Biomarker and treatment target for alcoholic hepatitis
AssigneeThe Regents of the University of California
InventorsBernd Schnabl, Ana Cristina Llorente Izquierdo
Life of this patent
Estimating the term…
Abstract
Methods of detecting and monitoring the progression of liver disease, including time to death, and methods of treating liver disease, in a mammal are provided.
Claims14
A method to predict time to death, to detect liver disease severity or to detect a need for therapy in a mammal with liver disease, comprising:
- detecting or determining a presence or an amount of Enterococcus faecalis cytolysin or cytolytic Enterococcus faecalis in a fecal, liver or blood sample of the mammal, wherein the presence or the amount of Enterococcus faecalis cytolysin or cytolytic Enterococcus faecalis is indicative of a decreased time to death, an increased risk of severe liver disease or a need for therapy in the mammal relative to a mammal that does not have liver disease or a mammal that does not have Enterococcus faecalis cytolysin in a fecal, liver or blood sample.
A method to detect progression of liver disease in a mammal, comprising:
- detecting over time an amount of Enterococcus cytolysin or cytolytic Enterococcus faecalis in a fecal, liver or blood sample of the mammal;
- and determining whether the amount over time increases.
A method to treat alcoholic hepatitis, NASH, liver cirrhosis, or liver failure, viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and metabolic liver diseases including hemochromatosis, a1-antitrypsin deficiency, or Wilson disease in a mammal, comprising:
- administering to the mammal an effective amount of a composition comprising one or more lytic phage specific for Enterococcus faecalis.
A method to monitor therapeutic efficacy in a mammal with liver disease, comprising:
- providing a mammal with liver disease that is treated with a. drug regimen or a liver transplant;
- and monitoring levels of Enterococcus cytolysin or cytolytic Enterococcus faecalis in the feces or blood of the mammal over time, wherein a decrease in Enterococcus cytolysin or cytolytic Enterococcus faecalis levels over time is indicative of efficacy.
Dependencies are inferred from the claim text.